

TARGETED GENETICS CORP /WA/

Form 8-K

March 15, 2006

Table of Contents

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

**FORM 8-K  
CURRENT REPORT**

**Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported) March 14, 2006**

**Targeted Genetics Corporation**

(Exact name of registrant as specified in its charter)

**Washington**

**0-23930**

**91-1549568**

(State or other jurisdiction  
of incorporation)

(Commission File  
Number)

(IRS Employer  
Identification No.)

**1100 Olive Way, Suite 100, Seattle, Washington**

**98101**

(Address of principal executive offices)

(Zip Code)

Registrant's telephone number, including area code **(206) 623-7612**

**Not Applicable**

(Former name or former address if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**TABLE OF CONTENTS**

Item 8.01. Other Events

Item 9.01. Financial Statements and Exhibits

SIGNATURES

INDEX TO EXHIBITS

EXHIBIT 99.1

---

**Table of Contents**

**Item 8.01. Other Events.**

On March 14, 2006, Targeted Genetics announced that it completed a public offering of approximately 12.8 million shares of its common stock at a price of \$0.39 per share to institutional investors, for gross proceeds of approximately \$5 million. A copy of Targeted Genetics press release announcing the completion of the public offering is attached as Exhibit 99.1 to this current report and is incorporated herein by reference.

**Item 9.01. Financial Statements and Exhibits.**

Exhibits.

99.1 Press Release of Targeted Genetics Corporation dated March 14, 2006

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Targeted Genetics Corporation

By: /s/ David J. Poston  
David J. Poston  
Chief Financial Officer

Dated: March 14, 2006

---

**Table of Contents**

**INDEX TO EXHIBITS**

**Exhibit**

**Number**

**Description**

99.1

Press Release of Targeted Genetics Corporation dated March 14, 2006